1. Ramchandren, R., E. Domingo-Dom enech, A. Rueda, M. Trnen y, T. A. Feldman, H. J. Lee, M. Provencio, C. Sillaber, J. B. Cohen, K. J. Savage, et al. 2019. Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study. J. Clin. Oncol. 37: 1997 2007.
2. Kochenderfer, J. N., M. E. Dudley, S. H. Kassim, R. P. Somerville, R. O. Carpenter, M. Stetler-Stevenson, J. C. Yang, G. Q. Phan, M. S. Hughes, R. M. Sherry, et al. 2015. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an antiCD19 chimeric antigen receptor. J. Clin. Oncol. 33: 540 549.
3. Maude, S. L., N. Frey, P. A. Shaw, R. Aplenc, D. M. Barrett, N. J. Bunin, A. Chew, V. E. Gonzalez, Z. Zheng, S. F. Lacey, et al. 2014. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371: 1507 1517.
4. Porter, D. L., B. L. Levine, M. Kalos, A. Bagg, and C. H. June. 2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365: 725 733.
5. Marcus, R., A. Davies, K. Ando, W. Klapper, S. Opat, C. Owen, E. Phillips, R. Sangha, R. Schlag, J. F. Seymour, et al. 2017. Obinutuzumab for the first-line treatment of follicular lymphoma. N. Engl. J. Med. 377: 1331 1344.
6. Mohty, M., J. Gautier, F. Malard, M. Aljurf, A. Bazarbachi, C. Chabannon, M. A. Kharfan-Dabaja, B. N. Savani, H. Huang, S. Kenderian, et al. 2019. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. Leukemia 33: 2767 2778.
7. Srivastava, S., and S. R. Riddell. 2018. Chimeric antigen receptor T cell therapy: challenges to bench-to-bedside efficacy. J. Immunol. 200: 459 468.
8. Maude, S. L., T. W. Laetsch, J. Buechner, S. Rives, M. Boyer, H. Bittencourt, P. Bader, M. R. Verneris, H. E. Stefanski, G. D. Myers, et al. 2018. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378: 439 448.
9. Schuster, S. J., M. R. Bishop, C. S. Tam, E. K. Waller, P. Borchmann, J. P. McGuirk, U. J€ager, S. Jaglowski, C. Andreadis, J. R. Westin, et al; JULIET Investigators. 2019. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380: 45 56.
10. Locke, F. L., S. S. Neelapu, N. L. Bartlett, T. Siddiqi, J. C. Chavez, C. M. Hosing, A. Ghobadi, L. E. Budde, A. Bot, J. M. Rossi, et al. 2017. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol. Ther. 25: 285 295.
11. Park, J. H., I. Rivi ere, M. Gonen, X. Wang, B. S en echal, K. J. Curran, C. Sauter, Y. Wang, B. Santomasso, E. Mead, et al. 2018. Long-Term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378: 449 459.
12. Gardner, R. A., O. Finney, C. Annesley, H. Brakke, C. Summers, K. Leger, M. Bleakley, C. Brown, S. Mgebroff, K. S. Kelly-Spratt, et al. 2017. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129: 3322 3331.
13. Xu, X., Q. Sun, X. Liang, Z. Chen, X. Zhang, X. Zhou, M. Li, H. Tu, Y. Liu, S. Tu, and Y. Li. 2019. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front. Immunol. 10: 2664.
14. Beckwith, K. A., J. C. Byrd, and N. Muthusamy. 2015. Tetraspanins as therapeutic targets in hematological malignancy: a concise review. Front. Physiol. 6: 91.
15. van Spriel, A. B., S. de Keijzer, A. van der Schaaf, K. H. Gartlan, M. Sofi, A. Light, P. C. Linssen, J. B. Boezeman, M. Zuidscherwoude, I. Reinieren-Beeren, et al. 2012. The tetraspanin CD37 orchestrates the a(4)b(1) integrin-Akt signaling axis and supports long-lived plasma cell survival. Sci. Signal. 5: ra82.
16. van Spriel, A. B., K. L. Puls, M. Sofi, D. Pouniotis, H. Hochrein, Z. Orinska, K. P. Knobeloch, M. Plebanski, and M. D. Wright. 2004. A regulatory role for CD37 in T cell proliferation. Journal of immunology (Baltimore, Md.: 1950) 172: 2953 2961.
17. Sheng, K. C., A. B. van Spriel, K. H. Gartlan, M. Sofi, V. Apostolopoulos, L. Ashman, and M. D. Wright. 2009. Tetraspanins CD37 and CD151 differentially regulate Ag presentation and T-cell co-stimulation by DC. Eur. J. Immunol. 39: 50 55.
18. Lapalombella, R., Y. Y. Yeh, L. Wang, A. Ramanunni, S. Rafiq, S. Jha, J. Staubli, D. M. Lucas, R. Mani, S. E. Herman, et al. 2012. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell 21: 694 708.
19. Schwartz-Albiez, R., B. Dorken, W. Hofmann, and G. Moldenhauer. 1988. The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. Journal of immunology (Baltimore, Md.: 1950) 140: 905 914.
20. van Spriel, A. B., M. Sofi, K. H. Gartlan, A. van der Schaaf, I. Verschueren, R. Torensma, R. A. Raymakers, B. E. Loveland, M. G. Netea, G. J. Adema, et al. 2009. The tetraspanin protein CD37 regulates IgA responses and anti-fungal immunity. PLoS Pathog. 5: e1000338.
21. Barrena, S., J. Almeida, M. Yunta, A. L opez, N. Fern andez-Mosteir ın, M. Giralt, M. Romero, L. Perdiguer, M. Delgado, A. Orfao, and P. A. Lazo. 2005. Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia 19: 1376 1383.
22. Moore, K., S. A. Cooper, and D. B. Jones. 1987. Use of the monoclonal antibody WR17, identifying the CD37 gp40-45 Kd antigen complex, in the diagnosis of Blymphoid malignancy. J. Pathol. 152: 13 21.
23. Gaudio, E., C. Tarantelli, A. Arribas, L. Cascione, I. Kwee, A. Rinaldi, M. Ponzoni, R. Pittau Bordone, G. Stussi, D. Rossi, et al. 2016. Identification of anti-lymphoma biomarkers of response to the anti-CD37 antibody drug conjugate (ADC) IMGN529. Blood 128: 4187.
24. Pereira, D. S., C. I. Guevara, L. Jin, N. Mbong, A. Verlinsky, S. J. Hsu, H. Avi~na, S. Karki, J. D. Abad, P. Yang, et al. 2015. AGS67E, an anti-CD37 monomethyl auristatin E antibody-drug conjugate as a potential therapeutic for B/T-cell malignancies and AML: a new role for CD37 in AML. Mol. Cancer Ther. 14: 1650 1660.
25. Heider, K. H., K. Kiefer, T. Zenz, M. Volden, S. Stilgenbauer, E. Ostermann, A. Baum, H. Lamche, Z. K€upc€u, A. Jacobi, et al. 2011. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood 118: 4159 4168.
26. Zhao, X., R. Lapalombella, T. Joshi, C. Cheney, A. Gowda, M. S. Hayden-Ledbetter, P. R. Baum, T. S. Lin, D. Jarjoura, A. Lehman, et al. 2007. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 110: 2569 2577.
27. Hill, J. A., S. Giralt, T. R. Torgerson, and H. M. Lazarus. 2019. CAR-T - and a side order of IgG, to go? - immunoglobulin replacement in patients receiving CAR-T cell therapy. Blood Rev. 38: 100596.
28. Kochenderfer, J. N., M. E. Dudley, S. A. Feldman, W. H. Wilson, D. E. Spaner, I. Maric, M. Stetler-Stevenson, G. Q. Phan, M. S. Hughes, R. M. Sherry, et al. 2012. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119: 2709 2720.
29. Brentjens, R. J., I. Rivi ere, J. H. Park, M. L. Davila, X. Wang, J. Stefanski, C. Taylor, R. Yeh, S. Bartido, O. Borquez-Ojeda, et al. 2011. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118: 4817 4828.
30. Alcantara, M., M. Tesio, C. H. June, and R. Houot. 2018. CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells. Leukemia 32: 2307 2315.
31. Ying, Z., X. F. Huang, X. Xiang, Y. Liu, X. Kang, Y. Song, X. Guo, H. Liu, N. Ding, T. Zhang, et al. 2019. A safe and potent anti-CD19 CAR T cell therapy. Nat. Med. 25: 947 953.
32. Hudecek, M., D. Sommermeyer, P. L. Kosasih, A. Silva-Benedict, L. Liu, C. Rader, M. C. Jensen, and S. R. Riddell. 2015. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol. Res. 3: 125 135.
33. Guest, R. D., R. E. Hawkins, N. Kirillova, E. J. Cheadle, J. Arnold, A. O’Neill, J. Irlam, K. A. Chester, J. T. Kemshead, D. M. Shaw, et al. 2005. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. Journal of immunotherapy (Hagerstown, Md.: 1997) 28: 203 211.
34. Fitzer-Attas, C. J., D. G. Schindler, T. Waks, and Z. Eshhar. 1998. Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: optimal design for T cell activation. Journal of immunology (Baltimore, Md.: 1950) 160: 145 154.
35. Scarf o, I., M. Ormhøj, M. J. Frigault, A. P. Castano, S. Lorrey, A. A. Bouffard, A. van Scoyk, S. J. Rodig, A. J. Shay, J. C. Aster, et al. 2018. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. [Published erratum appears in 2018 Blood 132: 2527.] Blood 132: 1495 1506.
36. K€oksal, H., P. Dillard, S. E. Josefsson, S. M. Maggadottir, S. Pollmann, A. Fåne, Y. N. Blaker, K. Beiske, K. Huse, A. Kolstad, et al. 2019. Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma. Blood Adv. 3: 1230 1243.
37. Watanabe, K., S. Terakura, A. C. Martens, T. van Meerten, S. Uchiyama, M. Imai, R. Sakemura, T. Goto, R. Hanajiri, N. Imahashi, et al. 2015. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 z chimeric antigen receptor-modified effector CD81 T cells. J. Immunol. 194: 911 920.
38. Lenkei, R., J. W. Gratama, G. Rothe, G. Schmitz, J. L. D’hautcourt, A. Arekrans, F. Mandy, and G. Marti. 1998. Performance of calibration standards for antigen quantitation with flow cytometry. Cytometry 33: 188 196.
39. Wang, X., W. C. Chang, C. W. Wong, D. Colcher, M. Sherman, J. R. Ostberg, S. J. Forman, S. R. Riddell, and M. C. Jensen. 2011. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118: 1255 1263.
40. Sakemura, R., S. Terakura, K. Watanabe, J. Julamanee, E. Takagi, K. Miyao, D. Koyama, T. Goto, R. Hanajiri, T. Nishida, et al. 2016. A tet-on inducible system for controlling CD19-chimeric antigen receptor expression upon drug administration. Cancer Immunol. Res. 4: 658 668.
41. Gonzalez, L., N. Strbo, and E. R. Podack. 2013. Humanized mice: novel model for studying mechanisms of human immune-based therapies. Immunol. Res. 57: 326 334.
42. de Winde, C. M., M. Zuidscherwoude, A. Vasaturo, A. van der Schaaf, C. G. Figdor, and A. B. van Spriel. 2015. Multispectral imaging reveals the tissue distribution of tetraspanins in human lymphoid organs. Histochem. Cell Biol. 144: 133 146.
43. Wood, B. 2004. Multicolor immunophenotyping: human immune system hematopoiesis. Methods Cell Biol. 75: 559 576.
44. Richman, S. A., S. Nunez-Cruz, B. Moghimi, L. Z. Li, Z. T. Gershenson, Z. Mourelatos, D. M. Barrett, S. A. Grupp, and M. C. Milone. 2018. High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model. Cancer Immunol. Res. 6: 36 46.
45. Qian, L., D. Li, L. Ma, T. He, F. Qi, J. Shen, and X. A. Lu. 2016. The novel antiCD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing. Cell. Immunol. 304 305: 49 54.
46. Hudecek, M., M. T. Lupo-Stanghellini, P. L. Kosasih, D. Sommermeyer, M. C. Jensen, C. Rader, and S. R. Riddell. 2013. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin. Cancer Res. 19: 3153 3164.
47. Hosen, N., Y. Matsunaga, K. Hasegawa, H. Matsuno, Y. Nakamura, M. Makita, K. Watanabe, M. Yoshida, K. Satoh, S. Morimoto, et al. 2017. The activated conformation of integrin b7 is a novel multiple myeloma-specific target for CAR T cell therapy. Nat. Med. 23: 1436 1443.
48. Imai, C., K. Mihara, M. Andreansky, I. C. Nicholson, C. H. Pui, T. L. Geiger, and D. Campana. 2004. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18: 676 684.
49. Carpenito, C., M. C. Milone, R. Hassan, J. C. Simonet, M. Lakhal, M. M. Suhoski, A. Varela-Rohena, K. M. Haines, D. F. Heitjan, S. M. Albelda, et al. 2009. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. USA 106: 3360 3365.
50. Zhao, Z., M. Condomines, S. J. C. van der Stegen, F. Perna, C. C. Kloss, G. Gunset, J. Plotkin, and M. Sadelain. 2015. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28: 415 428.
51. Cooper, M. L., J. Choi, K. Staser, J. K. Ritchey, J. M. Devenport, K. Eckardt, M. P. Rettig, B. Wang, L. G. Eissenberg, A. Ghobadi, et al. 2018. An “off-theshelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia 32: 1970 1983.
52. Gomes-Silva, D., E. Atilla, P. A. Atilla, F. Mo, H. Tashiro, M. Srinivasan, P. Lulla, R. H. Rouce, J. M. S. Cabral, C. A. Ramos, et al. 2019. CD7 CAR T cells for the therapy of acute myeloid leukemia. Mol. Ther. 27: 272 280.
53. Xiong, W., Y. Chen, X. Kang, Z. Chen, P. Zheng, Y. H. Hsu, J. H. Jang, L. Qin, H. Liu, G. Dotti, and D. Liu. 2018. Immunological synapse predicts effectiveness of chimeric antigen receptor cells. [Published erratum appears in 2021 Mol Ther. 29: 1349 1351.] Mol. Ther. 26: 963 975.
54. Schwartz-Albiez, R., B. D€orken, W. Hofmann, and G. Moldenhauer. 1988. The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. J. Immunol. 140: 905 914.